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  Human IgG3 displays the strongest effector functions of all IgG subclasses but has a short 
half-life for unresolved reasons. Here we show that IgG3 binds to IgG-salvage receptor (FcRn), 
but that FcRn-mediated transport and rescue of IgG3 is inhibited in the presence of IgG1 due 
to intracellular competition between IgG1 and IgG3. We reveal that this occurs because of a 
single amino acid difference at position 435, where IgG3 has an arginine instead of the histidine 
found in all other IgG subclasses. While the presence of R435 in IgG increases binding to FcRn 
at neutral pH, it decreases binding at acidic pH, affecting the rescue efﬁ   ciency — but  only  in 
the presence of H435  –  IgG. Importantly, we show that in humans the half-life of the H435-
containing IgG3 allotype is comparable to IgG1. H435  –  IgG3 also gave enhanced protection 
against a pneumococcal challenge in mice, demonstrating H435  –  IgG3 to be a candidate for 
monoclonal  antibody  therapies.          
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 H
uman IgG3 activates complement and Fc  γ R-mediated 
functions more eff  ectively than any other subclass, followed 
by IgG1, IgG2 and IgG4, respectively, making it an ideal 
candidate for immunotherapy  1 – 4 . However the short half-life of one 
week for IgG3, compared with three weeks for the other subclasses, 
currently makes IgG1 the therapeutic subclass of choice  4,5 . 
 Th  e exceptionally long half-life of IgG is mediated by a single 
receptor, the neonatal Fc receptor for IgG (FcRn)  6,7  . FcRn is a het-
erodimer consisting of a unique MHC class-I like   α -chain,  associated 
with  β 2M. Because its affi   nity for IgG is negligible at physiological pH 
(  ~  7.4), FcRn binds to IgG only aft  er pinocytosis within early endo-
somes (pH   ≤ 6.5) 8,9  . FcRn  –  IgG complexes are then routed away from 
the lysosomal pathway  10 – 13  , and either cycled back to the cell surface 
or transported to the opposite side of the cell. Th   e vesicles fuse with the 
plasma membrane, returning the pH to   ~  7.4, and releasing IgG  14 – 16 . 
Besides IgG transport, FcRn enhances IgG-mediated phagocytosis as 
well as antigen presentation by both MHC class I and II  16 – 19 ,  and  has 
a key role in rescuing albumin from lysosomal degradation  20  .  
  Two theoretical explanations for the reduced half-life of IgG3 
have been suggested. First, the long hinge region of IgG3 might 
make it more prone to proteolytic degradation  4  . Second, the 
recycling of IgG3 by FcRn may be less effi   cient because of an amino 
acid diff  erence at position 435 — a key contact residue with FcRn and, 
in IgG1, IgG2 and IgG4, important for the pH-dependent forma-
tion of IgG  –  FcRn complexes through histidine protonation around 
pH   ≤  6.5 (refs     8, 9, 21, 22). IgG3 contains an arginine in this position 
(R435), and although both residues classify as positively charged, 
arginines, unlike histidines, do not deprotonate at neutral pH, 
theoretically resulting in IgG3 binding to FcRn being less pH-
dependent, leading to shortened half-life as described for various 
mutated IgG variants with increased affi   nity to FcRn at neutral 
pH (refs     8, 23). Previous experimental work indeed pointed to the 
involvement of R435, as human IgG1  –  Fc and scFv  –  IgG1  –  Fc frag-
ments bearing R435 showed reduced half-life in wild-type mice  24,25 . 
Human H435R  –  IgG4 variant was also reported to display an altered 
binding to rat FcRn  8  . However, species-incompatible FcRn were 
used in these studies; the exceptional long hinge of IgG3 was not 
present; and the underlying mechanisms were not explored  4,8,24 – 27 . 
  Here we investigate the diff  erence in FcRn-mediated transport 
and rescue of IgG1 and IgG3. Using human   in vitro   and   in vivo  
models, we observed  —  unexpectedly  —  that both IgG1 and IgG3 
show pH-dependent binding to FcRn, and that FcRn can transport 
IgG3 as effi   ciently as IgG1. However, when both IgG1 and IgG3 
are present, IgG1 inhibits FcRn-mediated IgG3 transport, lead-
ing to degradation of IgG3. Our data provide strong evidence that 
the presence of an arginine at position 435 in IgG3 is suffi   cient to 
explain its high rate of catabolism observed   in vivo .  Importantly, 
we show that the half-life of the H435-containing IgG3 allotype is 
comparable to IgG1 in humans. Using a mouse model for pneumo-
coccal pneumonia, we provide a proof of concept that IgG3  –  R435H 
can be utilized for IgG-based immunotherapies aiming at maximiz-
ing eff  ector functions.   
 Results  
  IgG1 interferes with IgG3 transport   .    To  study  FcRn-mediated 
functions, we developed an   in vitro   transport model by transducing 
the FcRn-negative human cell line A375 with the human FcRn 
  α -chain  (A375 – FcRn).  Th   e wild-type A375 did not transport IgG 
using intravenous immunoglobulin (IVIg), a polyclonal mixture of 
all human IgG subclasses (  Fig. 1a  ). However, active transport was 
observed in A375  –  FcRn cells in medium buff  ered at pH 7.4. We 
found IgG transport in A375  –  FcRn to be similar to that observed 
across placental syncytiotrophoblast derived JAR cells expressing 
endogenous FcRn ( Fig. 1b ). From IVIg, A375 – FcRn cells transported 
IgG3 less eff  ectively than IgG1, but JAR transported relatively equal 
amounts of both IgG1 and IgG3 (  Fig. 1a,b  ). 
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         Figure  1     |          IgG3  transport  is  inhibited  by  IgG1  at  non-saturating 
conditions. All experiments were performed at pH 7.4. (  a )  FcRn-negative 
human A375-WT cells did not transcytose IgG1 (white) and IgG3 
(hatched) from IVIg as transport was comparable to passive leakage (HRP, 
black). After transfection with the FcRn   α -chain,  A375 – FcRn  efﬁ  ciently 
transported IgG from the apical to the basolateral compartment. When 
IVIg was mixed with Z-domain before transport at a 2:1 molar ratio 
(Z-domain:IgG) the IgG1 transport by A375  –  FcRn cells was signiﬁ  cantly 
reduced, while IgG3 transport was enhanced. (  b  ) JAR cells naturally 
expressing FcRn transported IgG1 and IgG3 from IVIg equally well. 
Incubation of IVIg with the Z-domain at a 2:1 molar ratio before transport 
inhibited transport of IgG1 but increased transport of IgG3. (  c )  Puriﬁ  ed 
IgG3 and IgG1 were transcytosed equally well in A375  –  FcRn cells when 
transported separately, and neither inhibited its own transport when the 
input was doubled. Yet in 1:1 mixtures, IgG3 transport was reduced in 
the presence of IgG1. (  d  ) In JAR cells, IgG3 was efﬁ  ciently transported 
when offered alone. The amount of either IgG1 or IgG3 transported was 
also unaffected by doubling the apical concentration, but IgG3 transport 
was inhibited by the presence of equal amounts of IgG1. (  e  ) When only 
one subclass was present, A375  –  FcRn transported a ﬁ  xed percentage of 
IgG (left axis), while the absolute amount transported was diminished 
(IgG1 open squares, IgG3 triangles, right axis). Throughout, IgG1 is 
represented by open bars, IgG3 by hatched bars. 100       μ g   ml     −     1   IVIg was 
used in both (  a , b  ). Apical to basolateral transport of myeloma IgG1 and 
IMIg-derived IgG3 in the concentration indicated in (  c  –  e  ). The   Y -axis 
represents the percentage of IgG transported from the apical compartment 
to the basolateral compartment. The data represent mean and standard 
deviation from three independent experiments. Statistical comparison was 
performed by one-way ANOVA followed by Tukey  ’  s multiple comparison 
test in (  a , b  ), and transport of IgG3, in the presence of IgG1, was compared 
with transport of IgG3 alone by two-tailed   t  -test in (  c , d ).   *  P  ≤ 0.05;   *  *  P  ≤ 0.01; 
 *  *  *  P  ≤ 0.001.  ARTICLE   
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  When IVIg was pre-incubated with Z-domains of protein A, a 
selective competitive inhibitor of FcRn binding to IgG1, IgG2 and 
IgG4 (refs     28, 29), transport of IgG1 by JAR and A375  –  FcRn cells 
was reduced to levels approaching those found in parental A375-WT 
and for non-specifi  c horseradish peroxidase (HRP) transport and 
(  Fig. 1  ), indicating IgG1 transport to be FcRn-dependent in both 
cell types. Remarkably, IgG3 transport was signifi  cantly increased 
in both JAR and A375  –  FcRn cells by the addition of Z-domains 
(  Fig. 1a,b  ), suggesting that active transport of the other IgG 
subclasses interfered with IgG3 transport. 
  We therefore studied the eff  ect of IgG1 on the FcRn-mediated 
transport of IgG3 using purifi  ed antibodies. Indeed, IgG3 alone 
was transported equally well as IgG1, and the transport of IgG3 
was inhibited by adding IgG1 to A375  –  FcRn (  Fig. 1c  ) or JAR 
cells (  Fig. 1d  ). As the percentage of IgG1 or IgG3 transport was 
unaff  ected by the initial IgG concentration (measured over a range 
from 1 to 350        μ g   ml     −     1  ;   Fig. 1e  ) the observed inhibition of IgG3 
transport by IgG1 (at concentrations of 50  –  100       μ g   ml     −     1 )  cannot  be 
owing to FcRn saturation. Th   e pH in the extracelluar medium was 
set at pH 7.4, suggesting the inhibition to takes place in intracellular 
compartments.   
  IgG1 and IgG3 compete for binding to FcRn and transport   .     O b e r  
  et al.   demonstrated that, during sorting, the unbound FcRn mol-
ecules are routed away from the sorting endosomes  15 .  Th  is  might 
explain the observed competition between IgG1 and IgG3 for FcRn 
binding and transport, because the number of FcRn molecules in 
intracellular compartments can also become limited under non-
saturating conditions. Indeed, we show that when the IgG3 con-
centration was kept constant at 10        μ g   ml     −     1  , IgG1 concentrations 
as  low  as  1   ng   ml     −     1   signifi  cantly reduced IgG3 transport (  Fig. 2a  ). 
When IgG1 and IgG3 were mixed in equal amounts, the relative 
IgG3 transport was signifi  cantly reduced, compared with transport 
of IgG3 alone at high concentrations, but was unaff  ected at IgG 
concentrations of 10     ng     ml      −     1  / subclass,  when   ~ 4 %   of  1.25    μ m  sort-
ing endosomes  15  would be expected to contain IgG ( Fig. 2b ). Remark-
ably, this concentration of IgG1 (10     ng     ml      −     1 )  signifi  cantly inhibited a 
1,000-fold excess of IgG3 (10    μ g   ml     −     1 ,  Fig. 2a ). Similarly, soluble IgG1 
was more effi   cient than IgG3 in inhibiting binding of soluble human 
FcRn (shFcRn) to IgG3-immobilized biosensor chips (  Fig. 2c,d  ).     
  R435 in IgG interferes with binding to FcRn   .   When the diff  erences 
in position 435 between IgG1 (Histidine) and IgG3 (Arginine) were 
modelled into the existing crystal structure  21  , it was clear that the 
longer side chain of arginine may potentially disrupt the tight fi  t of 
IgG in the FcRn-binding pocket (  Fig. 3a,b  ). However, theoretically 
it may also convey a more favourable charge at pH 7.4, at which 
the net charge of histidine is neutral but arginine is positive  22 .  IgG3 
did indeed bind to shFcRn signifi  cantly better at pH 7.4, but IgG1 
bound better at pH 6.0 as measured by ELISA (  Supplementary Fig. 
S1  ) and by surface plasmon resonance (SPR) (  Fig. 3c,d  ). We subse-
quently mutated IgG1 to include the IgG3-derived arginine residue 
and vice versa (IgG1 – H435R and IgG3 – R435H, respectively). Th  ese 
mutations resulted in the loss (IgG1 – H435R) or gain (IgG3 – R435H) 
of protein A binding (  Supplementary Fig. S1  ). 
  Using shFcRn-coupled biosensor chips in SPR experiments, we 
noted that IgG1  –  H435R showed improved binding to FcRn at pH 
7.4 compared with WT IgG1, but reduced binding affi   nity at acidic 
pH. Likewise, binding of IgG3  –  R435H was reduced at pH 7.4, but 
improved at acidic pH compared with WT IgG3 (  Fig. 3c,d  ). Th  e 
relative binding of both IgG subclasses and variants was however 
very weak at pH 7.4, but increased steadily as the pH decreased, 
showing that shFcRn binding remained pH-dependent for all variants. 
 Th  e H435-containing IgG variants bound shFcRn with similar 
calculated affi   nities at pH 6.0 according to the bivalent ligand-bind-
ing model. However, IgG3 and IgG1  –  H435R had calculated kinetic 
dissociation  constant  (K     D
 s) that were, respectively, two times and 
  ~  50  %   higher than WT IgG1 (  Supplementary Fig. S2  ;   Supplemen-
tary Table S1  ). Similar results were found using the heterogeneous 
ligand-binding model and by repeating the experiments with a 
reversed set-up, using IgG-coupled biosensor chips and the steady-
state affi   nity model  30  : shFcRn bound the strongest to IgG1-coupled 
chips at pH 6.0 whereas IgG1  –  H435R showed reduced binding. Th  e 
affi   nity of shFcRn was improved for IgG3  –  R435H compared with 
IgG3 that showed the weakest affi   nity of all variants (  Fig. 4  ).     
  Th   e inhibition of IgG3 transport by IgG1 is due to R435   .    I n  a g r e e -
ment with the retained pH-dependent FcRn-binding, the presence 
of histidine or arginine at position 435 did not infl  uence the trans-
port effi   ciency of either subclass when transported individually in 
IgG1 molecules per vesicle
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     Figure  2     |          Concentration-dependent  inhibition  of  IgG3  transport  by  IgG1 
owing to competitive binding to FcRn. Apical to basolateral transport 
of V-gene matched recombinant IgG3 and IgG1. (  a  ) IgG3 concentration 
was kept constant (10       μ g   ml     −     1  ) in the absence or presence of increasing 
amounts of IgG1. IgG3 transport was inhibited up to a plateau when more 
than  1   ng   ml     −     1   IgG1 was present. All data points were compared with 
the samples without IgG1 by one-way ANOVA and Dunnett  ’  s multiple 
comparison test. (  b  ) Recombinant IgG3 alone (dotted line) or mixed with 
IgG1 (solid line) at a 1:1 ratio in increasing concentrations were added 
to the apical compartment and IgG3 was measured in the basolateral 
compartment. At concentrations lower than 1       μ g   ml     −     1  , transport of IgG3 
increased up to levels similar to those observed when IgG3 is transported 
alone. All data points from mixed IgG1 and IgG3 transport in (  b )  were 
compared by   t  -test to the corresponding IgG3 transport without IgG1 
present. The theoretical number of IgG molecules present in 1.25-
  μ  m-wide sorting endosomes described in ref.     15, assuming an equal 
concentration within these vesicles as present in the medium, is indicated 
on the secondary upper   x  -axis in (  a , b  ). This arbitrary value is given as an 
indication only as these calculated values cannot take miscellaneously 
elongated or tubule-tethered vesicles into account  13,15   ( c , d ).  Surface 
plasma resonance analysis showing binding of 100-nM recombinant 
shFcRn to IgG3-immobilized CM5 biosensor chips (1,300     RU) at pH 6.0 in 
the presence of increasing concentrations of 25, 50, 100, 200 or 400-nM 
recombinant soluble IgG1 (  c  ) or IgG3 (  d  ). The data in (  a , b  ) represent the 
mean and standard deviation. All experiments were repeated at least three 
times with similar results.   *    P  ≤ 0.05;   *  *  P  ≤ 0.01;   *  *  *  P  ≤ 0.001.  ARTICLE
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A375 – FcRn cells ( Fig. 5a ). When the amino acid at position 435 was 
mutated to an alanine, binding to protein A and shFcRn (  Supple-
mentary Fig. S1  ) as well as FcRn-dependent transport (  Fig. 5a  ), was 
almost entirely abrogated both for IgG1 and IgG3. When mixed, 
IgG1  –  H435A did not inhibit transport of IgG3 (  Fig. 5b  ), indicating 
that binding of IgG1 to FcRn was required for the observed inhibi-
tion of IgG3 transport. Importantly, IgG1  –  H435R (  Fig. 5a  ) was also 
unable to inhibit IgG3 transport (  Fig. 5b  ), indicating the arginine  /
 histidine diff  erence between IgG3 and IgG1 to be important for IgG1-
mediated inhibition of IgG3 transport. In line with this, transport of 
IgG3 – R435H  was  unaff  ected by the presence of any IgG1 variant 
( Fig.  5c ).  Remarkably,  IgG3 – R435H  inhibited  transport  of  IgG1 –
 H435R ( Fig. 5c ) to a similar extent as IgG1-WT inhibited transport of 
IgG3-WT (  Fig. 5b  ). Th   ese results demonstrate that IgG  –  R435 can be 
transported by FcRn through cells, but that binding to, and transport 
by, FcRn is inhibited in the presence of H435-containing IgG.     
  Competition for FcRn leads to degradation of IgG3   in vitro     .     We  
next tested whether the reduced IgG3 transport in the presence of 
IgG1 was refl  ected in enhanced degradation during apical to basola-
teral transport. We therefore measured the recovery of diff  erent IgG 
variants from the apical and basolateral compartments (  Fig. 6a  ). Up 
to 95  %   of IgG1 or IgG3 could be accounted for when transported 
alone. When mixed with IgG3, IgG1 recovery was unaff  ected, but 
only 60 %  of the initial amount of IgG3 was detected. However, when 
WT IgG1 and IgG3 – R435H were mixed, recovery of both was  ~ 95 %  
(  Fig. 6a  ), indicating that the decreased transport and enhanced loss 
of IgG3 in the presence of IgG1 was solely due to the arginine at 
position  435.   
  IgG3 with H435 has an enhanced half-life in humans   .     Th  e  IgG3 
G3m(  s , t  ) allotype (  Supplementary Fig. S3  ) contains a histidine at 
position 435, and can therefore be used to investigate the   in vivo  
eff  ect of the mutation. Although not commonly found in native 
Europeans, we found detectable levels in IVIg (  Supplementary 
Fig. S4 ).  31 – 34  We therefore investigated whether R435 can also cause 
the fast clearance of IgG3   in vivo  , by analysing the serum persist-
ence of this IgG3 allotype in sera of IVIg-treated X-linked agam-
maglobulinemic patients. Compared with the amounts found in 
the IVIg preparation itself, the amount of IgG1 and IgG2 relative to 
total IgG was unchanged in these patients four weeks aft  er the last 
infusion of IVIg (  Fig. 6b  ). As expected, the total serum IgG3 level, 
consisting mostly of R435 containing G3m(b) and G3m(g) allotypes 
in Europe  31,32   (  Supplementary Fig. S3  ), was signifi  cantly lowered, 
but signifi   cantly increased for the H435-containing IgG3 allo-
type G3m(  s , t )  ( Fig.  6b ).  Th   us, also in natural variants of IgG3, the 
presence of a histidine or an arginine at position 435 determines the 
catabolic rate   in vivo .   
  Enhanced eff  ector functions of H435 containing IgG3  in vivo     .    Ig G 3  
binds C1q and activates Fc γ R more potently than any of the other IgG 
subclasses, but its therapeutic application has not yet been consid-
ered a viable option because of its short half-life  4,35,36  . We therefore 
compared the potential of the recombinant V-gene-matched IgG1, 
IgG3, IgG1  –  H435R and IgG3  –  R435H (directed against   Streptococ-
cus pneumoniae   serotype 6)  17,37   to stimulate Fc  γ R-mediated  phago-
cytosis and mediate protection against pneumococcal pneumonia 
and bacteremia. IgG3 mediated more phagocytosis than IgG1, and 
neither isoallotypic alteration (IgG1 H435R  /  IgG3 R435H) signifi  -
cantly changed the capacity of the antibodies to mediate phagocy-
tosis of pneumococci (  Supplementary Fig. S5  ). We then passively 
immunized outbred NMRI mice 48     h before measuring the level of 
the human antibodies and intranasal challenge with virulent pneu-
mococci. Th   e serum persistence of all four IgG were measured before 
challenge that were found to be lower for IgG3 and IgG1  –  H435R 
than for IgG1 and IgG3  –  R435H (  Fig. 7a  ). Bacteremia and pneumo-
nia were determined 24     h later  37 .  IgG1  and  IgG3 – R435H  completely 
protected against bacteremia, whereas IgG3- and IgG1  –  H435R- 
treated mice were partly protected (  Fig. 7b  ). IgG3  –  R435H dem-
onstrated a signifi  cantly better protection against pneumonia than 
IgG1 and IgG3, whereas IgG1 – H435R was not protective ( Fig. 7c ). A 
complete clearance for a large fraction of the mice was only observed 
in the IgG3  –  R435H-treated group (  Fig. 7b,c  ). Th   e statistical analysis 
of the data in   Figure 7b   is displayed in   Table 1  . 
  Collectively, these data reveal that the short half-life described 
for human IgG3 is due to the arginine in position 435, that can be 
overcome by introducing an histidine present in this position in the 
G3m(  s , t  ) allotypes and other IgG subclasses. Th  e    in vivo   application 
of H435  –  IgG3 combines the properties of long half-life and strong 
eff  ector functions that surpasses that of human IgG1.       
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on FcRn binding at different pH. (  a  ) The crystal structure of FcRn with 
IgG  –  Fc part, showing the orientation of the amino acid 435 of IgG in yellow. 
  N  -linked glycans are labelled according to their occurrence in FcRn and Fc. 
(  b  ) A close-up showing the side chain of amino acid 435 of IgG (histidine, 
in green) in the binding pocket of FcRn. When arginine (present at this 
position in IgG3) was modelled into this position (yellow), it protrudes 
into the FcRn surface area (non-polar residues in white, positively charged 
amino acids in blue, negatively charged residues in red and polar residues 
in green), suggesting steric hindrance. Histidine at this position alters its 
charge at pH 6.5 and lower (positive charge, resulting in FcRn binding) 
versus neutral pH (no charge, resulting in release of IgG from FcRn)  22 . 
Arginine in this position, however, is positively charged at both low and 
neutral pH, possibly resulting in better binding of IgG3 at neutral pH. 
The crystallographic coordinates  51   (accession 1I1A) were modelled using 
DeepView 4.03 (ref.     52) and VMD 1.9 (ref.     53). (  c , d  ) The importance of 
this amino acid difference between IgG1 and IgG3 was tested biochemically 
by injecting 500     nM recombinant IgG over shFcRn-coupled CM5 sensor 
chips at different pH. IgG3 (  d  ) bound FcRn better than IgG1 (  c  ) at neutral 
pH, but the situation was reversed at acidic pH. IgG1  –  H435R mutant gained 
IgG3-like characteristics, binding better at neutral pH, but worse at low pH 
(  c  ). Likewise, IgG3 behaved like IgG1 after replacing the R435 with H435, 
binding relatively worse at neutral pH, but better at low pH (  d ),  conﬁ  rming 
that two opposing factors (steric hindrance versus charge) may contribute 
to the observed inhibition by IgG1 on FcRn-mediated IgG3 transport. The 
data in (  c , d  ) are presented as individual data points connecting the means 
from two independent injections with a line.   ARTICLE   
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 Discussion 
  In this study, we investigated the binding of IgG3 to FcRn, which, 
although slightly lower and less pH-dependent, was surprisingly 
similar to IgG1. In agreement with this, we found FcRn-mediated 
transport of purifi  ed IgG3 to be comparable to that of IgG1. Th  ese 
fi  ndings fail to explain the short half-life of IgG3 in humans. However, 
we found an unexpected inhibition of IgG3 transport in the presence 
of other IgG subclasses. Th   is was because of intracellular competition 
for FcRn-mediated transport owing to a single amino acid diff  erence 
in position 435 between IgG3(arginine) and the other IgG subclasses 
(histidine), which explains the shorter plasma half-life of IgG3. 
Mutating this arginine in IgG3 to histidine abrogated the inhibition 
by IgG1, without aff  ecting the superior eff  ector functions of IgG3. 
 FcRn-mediated transport and degradation were studied in hFcRn-
transfected human A375 cells and in the naturally FcRn-expressing 
human choriocarcinoma cellline JAR. Th   e transport rates of purifi  ed 
IgG1 and IgG3 were similar for various IgG sources. However, in both 
cell types, the transport of IgG3 was inhibited by addition of IgG1. 
Th   is inhibition was observed for myeloma IgG1 combined with IgG3 
purifi  ed from Intramuscular Ig (IMIg), for V-gene-matched recom-
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  Figure  4     |          Binding  of  the  IgG  at  pH  6.0  is  inﬂ  uenced by the amino acid at position 435. The different IgG variants (IgG1, IgG1  –  H435R, IgG3, or 
IgG3  –  R435H) were immobilized to CM5 sensor chips and shFcRn injected at different concentrations (7  –  4,000     nM represented by different lines) at pH 
6.0. The sensorgrams are shown in the left panels (  a  –  d  ), and the corresponding equilibrium-binding responses versus shFcRn concentrations in the right 
panels (  e  –  h  ), for IgG1 (  a , e ),  IgG1 – H435R  ( b , f  ), IgG3 (  c , g  ), or IgG3  –  R435H (  d , h  ). The calculated afﬁ  nity constants are superimposed in the right panels 
as derived from steady-state binding model using the BIAevaluation software. FcRn shows a reduced afﬁ  nity to IgG1 at pH 6.0 after mutating the H at 
position 435 to R, and enhanced afﬁ  nity to IgG3 after mutating the R at position 435 to H. The data are representative from two independent injections.   ARTICLE
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binant IgGs, and for IVIg in which the inhibition could be alleviated 
by a protein-A-based inhibitor of FcRn  –  IgG-binding (Z-domain) spe-
cifi  c for IgG1, IgG2 and IgG4. Th   e transport rate was independent of 
the IgG concentration indicating that an excess of FcRn over IgG will 
exist early aft  er internalization. However, Ober  et al.  showed that there 
is a progressive depletion of FcRn aft  er endo- or pinocytosis events as 
FcRn-containing vacuoles without IgG are routed away from sorting 
endosomes containing both IgG and FcRn  15  . Under these circum-
stances, competition between IgG1 and IgG3 for formation of FcRn  –
  IgG complexes could favour IgG1 binding at low pH (refs     21, 38, 39). 
 Signifi  cant transport inhibition of an excess of IgG3 was observed 
using very low concentrations of IgG1. Possibly this can be explained 
by recent fi  ndings showing that routing of IgG and FcRn does not 
take place inside discrete vesicles, but through elongated tubules 
and  /  or multiple recycling-endosomes tethered by tubules  13,15,39 . 
Here IgG probably binds FcRn in a stochiometry of 1:2, with two 
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         Figure  5     |          Inhibition  of  IgG3  transport  by  IgG1  is  due  to  R435  in  IgG3. 
(  a  ) Mutating the amino acid at position 435 in IgG1 (H435) and in IgG3 
(R435) to an alanine reduces transport, while exchanging the histidine 
native to IgG1 and the arginine native to IgG3 on each others backbone 
had no effect on their transport rate when offered separately to FcRn-
transfected A375 cells. (  b  ) Whereas transport of IgG3-WT was inhibited in 
the presence of IgG1-WT, IgG1 bearing an alanine or an arginine at position 
435 had no effect on IgG3 transport. (  c  ) Transport of IgG3 with a histidine 
at position 435 was not inhibited by WT IgG1. When the amino acids found 
at position 435 in IgG1 and IgG3 were swapped, IgG1  –  H435R transport 
was inhibited by IgG3  –  R435H. (  a  –  c )       ±        indicate the presence or absence 
of IgG (10       μ g   ml     −     1   per subclass), IgG1 is represented by open bars, IgG3 by 
hatched bars. The presence of mutated variants (435H, 435A and 435R) 
is indicated by the corresponding letter. The data represent mean and 
standard deviation from three independent experiments. Transport of WT 
IgG was compared with transport of mutant IgG by one-way ANOVA with 
Dunnett  ’  s multiple comparison test and signiﬁ   cance.   *  *  P  ≤ 0.01;   *  *  *  P  ≤ 0.001.  
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     Figure  6     |          H435-containing  IgG3  has  extended  half-life  in  humans. 
(  a  ) Approximately 95  %   of the total IgG added to apical compartments 
of conﬂ  uent A375  –  FcRn monolayers was recovered after 24     h from both 
the apical (grey) and the basolateral (white) compartments when the 
IgG1 (open bars) or IgG3 (hatched) were added individually (10       μ g   ml     −     1  
per subclass). However, when the IgG1 and IgG3 were mixed in equal 
amounts,   ~  65  %   of the initial IgG3 could be detected, suggesting IgG3 
was degraded in the presence of IgG1. IgG1 recovery was similar to that 
found when no IgG3 was present. IgG3  –  R435H was not degraded in the 
presence of IgG1 as about 95  %   could be detected after 24     h, similarly 
to IgG3 alone. The data represent mean and standard deviation from 
three independent experiments. (  b  ) The relative concentration of IgG 
subclasses and the histidine-435 containing IgG3 allotype G3m(  s , t  ) in sera 
from agammaglobulinemic patients four weeks after their last treatment 
with IVIg compared with IgG subclass and G3m(  s , t  ) levels found in the 
corresponding IVIg preparation. Data represent the average plus standard 
deviation calculated from at least three independent IgG subclass and 
allotype measurements performed on serum from three patients in 
(  b  ). Statistical comparison was performed by one-way ANOVA followed 
by Tukey  ’  s multiple comparison test in (  b ).   *  P  ≤ 0.05;   *  *  *  P  ≤ 0.001.  For 
simplicity, signiﬁ  cant differences are only displayed for IgG1 compared 
with all subclasses, and between IgG3 total and G3m(  s , t  ) levels in (  b ).  ARTICLE   
7
NATURE  COMMUNICATIONS   |     DOI:   10.1038/ncomms1608 
NATURE COMMUNICATIONS   |   2:599   |     DOI:   10.1038/ncomms1608    |   www.nature.com/naturecommunications
© 2011 Macmillan Publishers Limited. All rights reserved.
FcRn molecules on parallel membranes binding to one IgG mol-
ecule  21,39  . If IgG in transit goes through multiple checkpoints in 
tubule-tethered recycling-endosomes  15  , then competition between 
IgG3 and IgG1 may occur sequentially. Diff  erences in on-rates were 
the most prominent fi  nding from the interaction kinetics studies, 
and this may at least partly explain the ability of low concentrations 
of IgG1 to inhibit IgG3-transport. Our fi  ndings that reduced IgG3 
transport in the presence of IgG1 coincides with enhanced IgG3 
degradation, support the hypothesis that this eff  ect occurs aft  er 
uptake and within developing lyso- and  /  or sorting endosomes. 
 We found that mutating position 435 in IgG to an alanine-reduced 
transport almost to background levels and that IgG1  –  H435A 
was unable to inhibit FcRn-mediated IgG3 transport. Transport-
inhibition of IgG3 by IgG1 was completely reversed by swapping 
the amino acids normally present in IgG1 and IgG3 at position 435 
(resulting  in  IgG1 – H435R  and  IgG3 – R435H).  Th  is strongly indi-
cated that human IgG1 is more adept at FcRn-mediated transport 
than IgG3, solely because of the R present at position 435 in IgG3. 
R435-containing IgG also bound shFcRn with a slightly lower 
affi   nity than H435-containing IgGs, and soluble IgG1 was better 
than IgG3 in inhibiting binding of shFcRn to solid-phase immo-
bilized IgG3. Th   is amino acid diff  erence was found to aff  ect IgG3 
binding to FcRn in two ways  —  likely through reduced sensitivity to 
deprotonation resulting in enhanced binding at pH 7.4, and through 
steric hindrance, causing decreased binding at pH 6.0, suggesting 
IgG3 to have a decreased competitiveness for pH-dependent FcRn 
binding and release, and thus for the overall transport. 
  To study whether our   in vitro   observations also apply   in vivo ,  we 
analysed sera from agammaglobulinemic patients who receive reg-
ular IVIg replacement therapy that contain both R435- and H435-
bearing IgG3 allotypes. We measured the relative IgG subclasses, 
and IgG3 allotype levels found in IVIg and sera, four weeks aft  er the 
previous IVIg dose was given. In agreement with our  in vitro  fi ndings, 
we found that these sera were enriched for the H435-containing IgG3 
allotypes compared with total IgG3, demonstrating that the R435 is 
also responsible for the lack of competitive FcRn-mediated rescue 
and short half-life of IgG3 in humans. In accordance with this, we 
found the serum persistence of IgG1 and IgG3 R435H to be higher 
than that of IgG3 and IgG1 H435R in outbred NMRI mice. Fur-
thermore, these fi  ndings show that the longer hinge of IgG3 does 
not lead to increased proteolytic degradation, which has been 
postulated to contribute to the lower half-life of IgG3 (ref.     4). 
  IgG3 binds Fc  γ  RIII and C1q with higher affi   nity than IgG1 and 
is capable of mediating considerably stronger eff  ector functions, 
such as antibody-dependent cellular cytotoxicity, respiratory burst 
phagocytosis  1,36,40 – 42  , and complement-dependent cytotoxicity 
towards tumour cells  3,43 .  Th  is suggests IgG3 containing H435 to 
be a more eff  ective candidate for   in vivo   immunotherapies. In an 
  in vivo   model of IgG-mediated protection against pneumococ-
cal sepsis and bacteremia WT IgG3 gave comparable protection 
against pneumonia as IgG1. However, IgG3  –  R435H protected mice 
signifi  cantly better than either IgG1 or IgG3 against pneumococcal 
pneumonia, correlating both with its enhanced eff  ector functions 
and half-life in mice, and confi  rming its therapeutic potential  24 . 
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      Figure  7     |          H435-containing  IgG3  has  increased  serum  persistence  in 
mice and protects against pneumococcal pneumonia. (  a  ) Serum IgG 
levels 48     h after injecting 1       μ  g the IgG variants into outbred NMRI mice. 
IgG1  –  H435R and IgG3 show lower serum levels than IgG1 and IgG3  –
 R453H.   *  *  P  ≤ 0.01;   *  *  *  P  ≤ 0.001.  ( b  ) Three and (  c  ) two experiments, showing 
outbred NMRI mice (8  –  10 per group per experiment) that were passively 
immunized intraperitoneally with 3       μ  g (circles symbols) or 1       μ g  (diamond) 
recombinant IgG anti-  Streptococcus pneumoniae   6 or placebo 48     h before 
challenge with pneumococci of serotype 6A. Results from individual 
experiments are shown using the same symbol throughout (open or closed 
circles and diamonds). The number of bacteria found in (  b  ) blood and (  c ) 
lungs 24     h after challenge are shown. (  b  ) All but one mouse in the control 
group developed bacteremia, while all but four mice receiving WT IgG1 
and all but one mouse receiving IgG3  –  R435H were completely protected. 
Approximately half of the mice receiving either IgG1  –  H435R or WT IgG3 
developed bacteremia. (  c  ) High numbers of bacteria were found in the 
lungs of control mice. All IgG-treated mice were signiﬁ  cantly protected 
from lung infection, with lowered level of bacterial burden, with few mice in 
each group completely protected with no detectable bacteria. IgG3  –  R435H 
protected the mice signiﬁ  cantly better than all other IgG variants, with ﬁ  ve 
mice without detectable lung or blood infection. The dotted lines indicate 
the level of detection. Data in (  a  ) represent the IgG levels in individual mice 
together with means and standard errors of means; data in (  b , c )  represent 
the bacterial load of individual mice together with medians (assuming 
the level of detection for individuals without detectable bacteria) and 
interquartile ranges, statistical comparison is tabulated in   Table 1  .   ARTICLE
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  In summary, IgG3 is known for both its superior eff  ector func-
tions compared with IgG1  —  the most commonly used isotype used 
for immunotherapy  —  but also for its short   in vivo   half-life 4,5,35,36 . 
We now show that FcRn can in fact rescue and transcytose IgG3 as 
effi   ciently as IgG1, but not in the presence of the other IgG subclasses. 
Our data support a model where IgG3 loses competition for FcRn 
binding and routing away from the lysosomal pathway, explaining 
its high catabolism  in vivo . We demonstrate that this can be resolved 
by replacing the R435 with a histidine, as is the case in a rare natu-
ral variant. Th   e epitope comprising the H435 in G3m(  s , t  ) is an iso-
allotype that is found in all other IgG subclasses, and its detectable 
presence in IVIg has not been documented to cause adverse reac-
tions in patients. Th   e extended half-life of the IgG3  –  R435H variant 
has important implications for current and future antibody-based 
therapies aimed at achieving maximal eff   ector  functions.   
 Methods  
  Cell culture      .     Human choriocarcinoma cells (JAR, ATCC, VA) were grown in 
  IMDM medium   (  Cambrex  ) and melanoma cells (A375, FcRn      −       β 2m     +      ,  ATCC) 
in   RPMI 1,640 medium   (  Invitrogen  /  Gibco  ), both supplemented with   l-glutamin   
(300    μ g   ml     −     1 ,   Invitrogen ),   penicillin   (100   U   ml     −     1 ,   PAA  Laboratories ),   streptomycin  
(100    μ g   ml     −     1 ,   PAA )  and  10 %    foetal  calf  serum   ( FCS ).   
  A375 – FcRn      .     Human FcRn messenger RNA was amplifi  ed aft  er fi  rst strand cDNA 
synthesis by PCR using the forward 5  ′ -GGATCCACCATGGGGGTCCCGCGGCC
TCAGC-3  ′   and reverse 5  ′ -GAATTCTCAGGCGGTGGCTGGAATCAC-3 ′   primers 
and ligated into pGEM-T (Promega, Madison, WI, USA). Th  e    Bam HI –  Eco RI  frag-
ment was subcloned into the   pMX-puro vector   (  DNAX  ) and transfected together 
with a packaging vector into 293T-cells  44  . Supernatants were used to transduce 
A375 cells  45  . Expression of FcRn was confi  rmed by quantitative RT  –  PCR  17    .
  IgG      .       IVIg   was obtained from   Sanquin  . Pooled myeloma IgG1 was purifi  ed from 
three multiple myeloma patients by serum protein precipitation and depletion of 
other subclasses by sephadex-bound anti-subclass Ig. IgG3 was obtained from   IMIg   
( Sanquin )  aft  er depleting other IgG with protein A. 
  Recombinant IgG1, IgG3 and IgG1  –  H435A have been described before  17,37 . 
Recombinant IgG were produced in   293 Freestyle cells   (  Invitrogen  ) according to 
the manufacturer  ’  s instructions, and purifi  ed using HiTrap protein A (for H435-
containing IgGs) or protein G using the   Acta Prime Plus system   (  GE Healthcare  ). 
IgG1 – H435R,  IgG3 – R435A  and  IgG3 – R435H  were  generated  using  the   Quick-
change Site-directed-mutagenesis kit   (  Stratagene  ) with the following and reverse 
complementary oligonucleotide primers: 
 IgG1 – H435R:   GAGGCTCTGCACAACC G CTACACGCAGAAGAGCC 
 IgG3-R435A:   GAGGCTCTGCACAAC GC CTACACGCAGAAGAGCC 
 IgG3 – R435H:   GAGGCTCTGCACAACC A CTACACGCAGAAGAGCC 
  All mutations were confi  rmed by sequencing before expression. Th   e endotoxin levels 
of the various batches was tested and confi  rmed to be very low or absent by measur-
ing IL-6 production of monocyte-derived immature DC, as described in ref.     46.     
  Z domain   .     Th   e gene encoding the Z-domain was amplifi  ed by PCR from the vector 
pTh  io-His-ZZ  47   using 5  ′ -GGATCCGTAGACAACAAATTCAAC-3 ′   (forward) 
and 5  ′ -CTGCAGTTATTTCGGCGCCTGAGCATC-3 ′   (reverse), and cloned into 
 pGEM-T   ( Promega ).  Th  e    Bam HI –  Not  I fragment was cloned into the pGEX 6.2 
expression vector and expressed in   Escherichia coli .  Th   e GST tag was removed using 
  PreScision protease   (  GE healthcare  ) and the Z-domain eluted off   the   glutathione 
sepharose 4B column   (  GE healthcare  ) by gravity fl  ow and dialysed against PBS.     
  IgG transcytosis   .    12   mm   polycarbonate  Transwell  fi  lters   (0.4       μ  m pore size,   Costar  /
  Corning  ) were inoculated with 5  ×  10  5   cells, grown overnight to confl  uence, washed 
with PBS and medium replaced with fresh 1.5     ml medium basolaterally and 0.5     ml 
apically (IMDM at pH 7.4 with supplements as stated above). Mixtures of IgG 
contained 125 pg     ml      −     1    streptavidin-HRP   ( Sanquin )  to  assess  background  transport. 
Apical to basolateral transport was calculated according to ([IgG]  basolateral  × 1.5   ml) /
 ([IgG] input  × 0.5   ml) × 100 % .  All  experiments  were  performed  in  triplicate.   
  Surface plasmon resonance assays      .     All experiments were performed using a 
  Biacore     3000 instrument  ,   CM5 biosensor chips and amine coupling   as described 
by the manufacturer (  GE Healthcare  ). Injections were done using phosphate buff  er 
(67   mM  phosphate  buff  er, 0.15     M NaCl, 0.05  %   Tween20) at pH 6.0. Kinetic evalu-
ations were performed using immobilized shFcRn  –  GST (  ~  1,000     RU)  48,49 ,  and  IgG 
variants (2  –  500     nM) injected. Alternatively, IgG was immobilized (  ~  1,500     RU) and 
shFcRn injected (7  –  4,000     nM). For the competitive SPR assay, chips were coupled 
with IgG (  ~  1,300     RU) and shFcRn (100     nM) was injected alone or together with 
serial dilutions of IgG1 or IgG3. Binding at diff  erent pH was done in a phosphate 
buff  er with 500     nM IgG injected over immobilized shFcRn (  ~  2.000     RU). All experi-
ments took place at 20  –  60       μ l   min     −     1 ,  25 ° C,  and   HBS-P  buff   er   ( GE  Healthcare ) 
at pH 7.4 was used for regeneration. Binding analyses were performed using the 
BIAevaluation wizard soft   ware  4.1.   
  Agammaglobulinemia patients   .    Serum  samples  from  three  agammaglobuline-
mia patients, taken 4 weeks aft  er receiving IVIg, were assessed for IgG subclass 
levels which were expressed as relative IgG concentrations compared with that 
found in IVIg (Relative IgG levels at week 4 (  %  )       =       [IgG    S  ] W4  / [IgG   T  ] W4  / ([IgG   S  ] IVIg  /
 [IgG   T  ] IVIg  )  ×  100  %  , where W4 stands for serum at week 4 aft  er IVIg injection,   S   for 
Subclass and   T   for Total). Serum samples were anonymous rest material acquired 
during routine IgG-evaluation of these patients, and, therefore, did not require a 
Medical Ethical Committee evaluation according to the institutional Committee 
of the Academic Medical Centre of the University of Amsterdam.     
  IgG quantiﬁ  cation      .     IgG subclass concentrations in sera were determined by 
Nephelometry (  Behringer Nephelometer II  ,   Behringer diagnostics  ). For other 
experiments, IgG concentrations were determined by sandwich ELISA using 
subclass specifi  c mouse monoclonal antibodies (  IgG1:MH161-1; IgG3:MH163-1  , 
 Sanquin )  or   allotype-specifi  c monoclonal anti G3m(    s , t  )  32   ( 1.5A10 ,   Sanquin ,   Sup-
plementary Fig. S4  ) for capture.   Mouse-anti-IgG-HRP   (  Southern Biotech  ) was used 
for detection in all assays except the G3m(  s , t  ) ELISA where   mouse anti-IgG3-HRP 
  (  MH163-1  , Sanquin) was used. Concentration was read of standard curves made 
using the same IgG preparations used for transport or to treat patients.     
  Passive protection   .     Th   e pneumococcal infection model has been described 
before  37,50  . In brief, outbred   NMRI mice   (  Taconic  ) were passively immunized 
intraperitoneally with 3       μ  g of recombinant IgG (diluted in 200       μ  l PBS) or saline 
only, 48     h before challenge with a virulent pneumococcal strain of serotype 6A. 
Mice were anesthetized and challenged intranasally with 2  ×  10  7    CFU  pneumococci 
in 50       μ  l sterile 0.9  %   saline. Twenty-four hours aft  er challenge, the mice were killed 
and bacterial load evaluated by colony counting as described in refs     37, 50. All 
  in vivo   studies complied with the Animal Experimental Committee of Iceland 
According to the Act on Animal Welfare no 15  /  1994.     
  Statistical analysis and data sets      .     All data represent the mean and standard 
deviation of at least three independent experiments. All transcytosis assays con-
sisted of three replicates.   GraphPad Prism version 4.00 for Windows   (  GraphPad 
Soft  ware  ) was used for all statistical analysis. Signifi  cance was set at   P  ≤  0.05, and the 
level of signifi  cance is indicated on all fi  gures as   *    P  ≤ 0.05;   *  *  P  ≤ 0.01;   *  *  *  P  ≤ 0.001.                      
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